NMIBC Market Size

Aug 30, 2024

A high cure rate characterizes Non-muscle Invasive Bladder Cancer (NMIBC), yet there is a notable risk of recurrence and progression to muscle-invasive disease. Effective NMIBC management involves precise local resection, staging, and a risk-based approach with intravesical agents. The conventional gold standard fo...

Aug 26, 2024

The BCG vaccine, a significant medical breakthrough developed in the early 20th century, is derived from a strain of Mycobacterium bovis initially created by the University of Illinois as a vaccine against tuberculosis. For NMIBC, BCG is administered intravesically to reduce the risk of cancer recurrence and progre...

Apr 01, 2024

Non-muscle-invasive bladder cancer represents a category of bladder cancer where the tumor is confined to the innermost layer of the bladder lining without invading the muscle. This early-stage form accounts for a significant proportion of bladder cancer cases. Among the 7MM, the US accounted for the highest num...

Oct 12, 2020

After 40 years of the introduction of the BCG immunotherapy, it continues to remain as the gold standard of the treatment of Non-muscle invasive bladder cancer (NMIBC). However, BCG intravesical therapy fails to yield responses in more than 50% of the NMIBC patients. After a shocking failure of BCG, cystectomy is p...